Showing 2111-2120 of 4166 results for "".
- Call for Nominations Issued for the 2020 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/call-for-nominations-issued-for-the-2020-bonnie-strickland-champion-for-childrens-vision-award/2477595/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the sixth annual “Bonnie Strickland Champion for Children’
- Hoya Vision Care Plans $25 Million Dollar Expansion of U.S. Labhttps://modernod.com/news/hoya-vision-care-plans-25-million-dollar-expansion-of-u-s-lab/2476833/Hoya Vision Care announced plans to invest more than $25 million in its Ramsey, Minnesota facility, according to a report in VisionMonday. The investment in facility
- Samsara Vision Launches PERSPECTIVE Trial, Achieves First Implant of SING IMT in Pseudophakic Patienthttps://modernod.com/news/samsara-vision-launches-perspective-trial-achieves-first-implant-of-sing-imt-in-pseudophakic-patient/2484154/Samsara Vision announced the initiation and successful first surgery of the PERSPECTIVE clinical trial. The study will evaluate the safety and efficacy of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in pseudophakic patients.
- Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RPhttps://modernod.com/news/nanoscope-therapeutics-announces-first-patient-dosed-in-phase-2b-trial-of-optogenetic-gene-monotherapy-to-restore-vision-in-patients-with-rp/2479381/Nanoscope Therapeutics announced that the first patient had been dosed in its phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigme
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- The Vision Council Scholarship Fund Expands Within the National Federation of Opticianry Schools; Launches Grassroots Marketing Effort to Reach Studentshttps://modernod.com/news/the-vision-council-scholarship-fund-expands-within-the-national-federation-of-opticianry-schools-launches-grassroots-marketing-effort-to-reach-students/2480840/The Vision Council announced that it is expanding the
- J&J Vision Announces New Collaboration Aimed at Eliminating Inequities in the Eye Care Industryhttps://modernod.com/news/johnson-johnson-vision-announces-new-collaboration-aimed-at-eliminating-inequities-in-the-eye-care-industry/2480280/Johnson & Johnson Vision announced a collaboration with
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- Johnson & Johnson Vision Appoints Rajesh K. Rajpal, MD, Chief Medical Officerhttps://modernod.com/news/johnson-johnson-vision-appoints-rajesh-k-rajpal-md-chief-medical-officer/2477634/Johnson & Johnson Vision has appointed Rajesh K. Rajpal, MD, as Chief Medical Officer and Global Head of Clinical and Medical Affairs. In this role, Dr. Rajpal will lead the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of pa
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held